摘要
目的观察瑞舒伐他汀对脑出血患者沉默信息调节因子2同源蛋白1/核转录因子-κB(SIRT1/NF-κB)通路及预后的影响。方法前瞻性选择南阳市第一人民医院2022年3月至2024年10月收治的92例脑出血患者作为研究对象,开展临床对照试验,通过电子随机化系统将入组患者分为常规组和联合组,每组46例。两组均实施颅内血肿清除术,常规组术后实施常规脑保护治疗,联合组采用瑞舒伐他汀联合常规脑保护治疗。比较两组SIRT1/NF-κB通路蛋白、炎症因子、治疗情况及预后情况,分析SIRT1/NF-κB通路蛋白与炎症指标的相关性。结果治疗后,联合组的SIRT1相对表达量高于常规组,NF-κB相对表达量低于常规组(P<0.05);联合组的肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素1β(IL-1β)均低于常规组,白细胞介素-10(IL-10)高于常规组(P<0.05)。联合组治疗14 d后、30 d后的血肿周围水肿体积(PHEV)均低于常规组,血肿吸收速率(HRR)均高于常规组(P<0.05)。联合组的药物不良反应发生率与常规组比较,差异无统计学意义(P>0.05)。截至随访结束时,联合组的神经功能缺损量表(NIHSS)评分、改良Rakin量表(mRs)评分均低于常规组(P<0.05)。SIRT1与TNF-α、IL-6、IL-1β、PHEV、NIHSS评分、mRs评分负相关,与IL-10、HRR正相关(P<0.05);NF-κB与TNF-α、IL-6、IL-1β、PHEV、NIHSS评分、mRs评分正相关,与IL-10、HRR负相关(P<0.05)。结论瑞舒伐他汀可通过调控SIRT1/NF-κB通路信号而减轻脑出血患者的炎症反应,对降低患者PHEV、提升HRR并改善患者预后均有积极影响。
Objective To observe the effect of rosuvastatin on the silencing regulatory factor 2 homologous protein 1/nuclear transcription factor-κB(SIRT1/NF-κB)pathway and prognosis in patients with cerebral hemorrhage.Methods A total of 92 patients with cerebral hemorrhage admitted to The First People's Hospital of Nanyang from March 2022 to October 2024 were prospectively selected as the research subjects.The enrolled patients were randomly divided into the conventional group and the combined group by an electronic randomization system,with 46 cases in each group.Both groups were treated with intracranial hematoma evacuation,the conventional group received conventional brain protection treatment after the operation,while the combined group was treated with rosuvastatin combined with conventional brain protection treatment.The SIRT1/NF-κB pathway proteins,inflammatory factors,treatment conditions and prognosis of the two groups were compared,and the correlation between SIRT1/NF-κB pathway proteins and inflammatory indicators were analyzed.Results After treatment,the relative expression levels of SIRT1 in the combined group were higher than those in the conventional group,and the relative expression levels of NF-κB were lower than those in the conventional group(P<0.05).The levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and interleukin-1β(IL-1β)in the combined group were lower than those in the conventional group,while interleukin-10(IL-10)was higher than that in the conventional group(P<0.05).The perihematoma edema volume(PHEV)of the combined group after 14 days and 30 days of treatment were lower than those of the conventional group,and the hematoma absorption rate(HRR)were higher than those of the conventional group(P<0.05).The incidence of drug adverse effects in the combined group was not significantly different from that in the conventional group(P>0.05).As of the end of follow-up,the NIHSS scores and the modified Rakin scale(mRs)scores of the combined group were lower than those of the conventional group(P<0.05).SIRT1 was negatively correlated with TNF-α,IL-6,IL-1β,PHEV,NIHSS scores,and mRs scores,and positively correlated with IL-10 and HRR(P<0.05);NF-κB was positively correlated with TNF-α,IL-6,IL-1β,PHEV,NIHSS scores,and mRs scores,and negatively correlated with IL-10 and HRR(P<0.05).Conclusion Rosuvastatin can alleviate the inflammatory response in patients with cerebral hemorrhage by regulating the SIRT1/NF-κB signaling pathway,and has a positive effect on reducing PHEV,improving HRR,and improving patient prognosis.
作者
岁轲轲
孙贺
SUI Keke;SUN He(The First People's Hospital of Nanyang,Nanyang Henan 473000,China)
出处
《药品评价》
2025年第12期1519-1523,共5页
Drug Evaluation
基金
河南省医学科技攻关项目(LHGJ2020201030)。
关键词
脑出血
瑞舒伐他汀
沉默信息调节因子2同源蛋白1/核转录因子-κB
炎症反应
预后情况
Cerebral hemorrhage
Rosuvastatin
Silencing regulatory factor 2 homologous protein 1/nuclear transcription factor-κB
Inflammatory response
Prognosis
